A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/18 A61P37/02

C12Q1/68

G01N33/68

C12Q1/00

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbo's)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data, Sequence Search

C. DOCUM	NTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.
X	DATABASE EMBL [Online] Mus musculus axotrophin mRNA, complete cds. 15 June 1999 (1999-06-15), HAENDEL ET AL.,: "Insertional mutagenesis of a novel gene, axotrophin, causes callosal RT agenesis and neural degeneration" XP002338547 Database accession no. AF155739 abstract	8
X	DATABASE EMBL [Online] Hypothetical protein FLJ12911 (Axotrophin) 1 March 1999 (1999-03-01), XP002338548 Database accession no. Q9H992 Homo sapiens abstract	

	-/		
Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.		
Special categories of cited documents:  A document defining the general state of the art which is not considered to be of particular relevance  E earlier document but published on or after the International filling date  L document which may throw doubts on priority ctaim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  O document referring to an oral disclosure, use, exhibition or other means  P document published prior to the international filing date but later than the priority date claimed	"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family		
Date of the actual completion of the international search  2 August 2005	Oate of mailing of the International search report  1 2. 08. 05		
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswljk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Mateo Rosell, A.M.		

Form PCT/I-SA/210 (second sheet) (January 2004)

International Application No
PCE EP2005/000934

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Category *	Gianos of document, with moleculor, where appropriate, or the resevant passages		
X	DATABASE EMBL [Online] Axotrophin (March 7 protein) 1 November 1999 (1999-11-01), XP002338549 Database accession no. Q9WV66 Mus musculus abstract	8	
X	RAMALHO-SANTOS M ET AL: "Stemmess: transcriptional profiling of embryonic and adult stem cells" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 298, no. 5593, 18 October 2002 (2002-10-18), pages 597-600, XP002327804 ISSN: 0036-8075 cited in the application table 1	8	
<b>X</b>	DATABASE Geneseq [Online] 26 June 2001 (2001-06-26), "Human protein sequence SEQ ID NO:17375." XP002338550 retrieved from EBI accession no. GSN:AAB95234 Database accession no. AAB95234 abstract & EP 1 074 617 A (RESEARCH ASSOCIATION FOR BIOTECHNOLOGY; HELIX RES INST) 7 February 2001 (2001-02-07)	8	
<b>X</b>	DATABASE Geneseq [Online] 12 February 2004 (2004-02-12), "Human MP53 protein sequence SEQ ID NO:59." XP002338551 retrieved from EBI accession no. GSN:ADF69089 Database accession no. ADF69089 abstract & WO 03/083047 A (EXELIXIS, INC; BELVIN, MARCIA; FRANCIS-LANG, HELEN; FRIEDMAN, LORI; PL) 9 October 2003 (2003-10-09)	8	
(	DATABASE Geneseq [Online] 20 January 2003 (2003-01-20), "Human polypeptide SEQ ID NO 1612." XP002338552 retrieved from EBI accession no. GSN:ABP69565 Database accession no. ABP69565 abstract -/	8	

International Application No
PEP2005/000934

		P( )EP2005/000934
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	-& WO 02/070539 A (HYSEQ, INC; TANG, Y., TOM; ZHOU, PING; GOODRICH, RYLE, W; ASUNDI, VINO) 12 September 2002 (2002-09-12) abstract page 1, line 30 - page 5, line 20 page 49, line 14 - page 54, line 30 page 210; sequence 1612	1-20
A	YAMASAKI SHINSUKE ET AL: "Characterization of a gene expressed in layer 5 of the neocortex." NEUROSCIENCE RESEARCH SUPPLEMENT, no. 26, 2002, page S109, XP008050575 & 25TH ANNUAL MEETING OF THE JAPAN NEUROSCIENCE SOCIETY; TOKYO, JAPAN; JULY 07, 2002-JULY 09, 2003 ISSN: 0921-8696 abstract	1
P <b>,</b> X	METCALFE S M ET AL: "Transplantation tolerance: gene expression profiles comparing allotolerance vs. allorejection" INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 5, no. 1, January 2005 (2005-01), pages 33-39, XP004678650 ISSN: 1567-5769 the whole document	1-20
T	METCALFE S M ET AL: "Leukaemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 579, no. 3, 31 January 2005 (2005-01-31), pages 609-614, XP004725165 ISSN: 0014-5793 the whole document	1-20



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple Inventions in this international application, as follows:
As all required additional search tees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 1,6 (6b) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition

.Although claims 5,12-14,16,17,19 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Information on patent family members

International Application No
PEP2005/000934

	Patent document cited in search report	Publication date		Patent family member(s)	Publication date
	EP 1074617	A 07-02-2001	AU AU	6180800 A 6180900 A	19-02-2001 19-02-2001
1		•	AU	6181000 A	19-02-2001
i			ΑÜ	6181100 A	19-02-2001
			AU	6181200 A	19-02-2001
			ΑU	6181300 A	19-02-2001
			AU	6181400 A	19-02-2001
			AU	6181500 A	19-02-2001
			AU	6181600 A	19-02-2001 19-02-2001
1			AU	6315800 A 2380472 A1	08-02-2001
			CA EP	1074617 A2	07-02-2001
			EP	1205549 A1	15-05-2002
İ			WO	0109315 A1	08-02-2001
			WO	0109345 A1	08-02-2001
			WO	0109316 A1	08-02-2001
			WO	0109349 A1	08-02-2001
			WO	0109317 A1	08-02-2001
			MO	0109318 A1	08-02-2001 08-02-2001
l			WO WO	0109319 A1 0109346 A1	08-02-2001
1			WO	0109340 A1	08-02-2001
			WO	0109321 A1	08-02-2001
1.			WO	0109322 A1	08-02-2001
			WO	0109323 A1	08-02-2001
}			JP	2002171977 A	18-06-2002
ļ			JP	2002191363 A	09-07-2002
			US	2003157569 A1 2003082776 A1	21-08-2003 01-05-2003
			US US	2003017480 A1	23-01-2003
	WO 03083047	A 09-10-2003	AU	2003213606 A1 2003216482 A1	13-10-2003 16-09-2003
			AU AU	2003210402 A1 2003223207 A1	16-09-2003
	•		AU	2003224638 A1	16-09-2003
			CA	2448112 A1	12-12-2002
			CA	2449479 A1	12-12-2002
			CA	2460944 A1	01-05-2003
			EP	1402051 A2	31-03-2004 31-03-2004
			EP	1402262 A2 1438432 A2	21-07-2004
			EP JP	2004532638 T	28-10-2004
			JР	2005514906 T	26-05-2005
			JP	2005506844 T	10-03-2005
			WO	02098889 A2	12-12-2002
			WO	02098468 A1	12-12-2002
			MO	02098891 A2	12-12-2002 12-12-2002
			WO WO	02099068 A2 03035831 A2	01-05-2003
			WO WO	03083047 A2	09-10-2003
			WO	03074662 A2	12-09-2003
			MO	03073823 A2	12-09-2003
			MO	03074674 A2	12-09-2003
			US	2003138431 A1	24-07-2003
			US	2003165966 A1	04-09-2003
			US	2003215849 A1	20-11-2003 27-11-2003
			US	2003219795 A1	C1-TT-COO3

Information on patent family members

International Application No
PC EP2005/000934

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02070539	A 12-09-2002	US 6783969 B1 CA 2440257 A1 EP 1381621 A2 WO 02070539 A2 WO 03029405 A2 US 2003032034 A1 US 2004053250 A1 US 2004005592 A1	31-08-2004 12-09-2002 21-01-2004 12-09-2002 10-04-2003 13-02-2003 18-03-2004 08-01-2004